Used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
Plerixafor inhibits the CXCR4 chemokine receptor and blocks binding to the marrow compartment of its cognate ligand, SDF-1alpha, which play a role in the trafficking and homing of human hematopoietic stem cells.
Plerixafor is rapidly absorbed after subcutaneous injection (Tmax = 30-60 min).
Terminal half-life ranges from 3 to 5 hours.
Approximately 70% of the parent drug is excreted in urine during first 24 h.
The apparent volume of distribution of plerixafor is 0.3 L/kg.